10-Q: Gaxos.AI Q3 Revenue Soars on Health & AI Growth, Losses Widen

Gaxos.AI reported a significant revenue increase in Q3 2025 driven by its RNK Health and subscription services, though net losses also expanded due to higher operating expenses.

Summary

• Total revenues for the three months ended September 30, 2025, surged to $498,271 from $2,704 in the prior year period, an increase of over 18,000%.
• Nine-month revenues also saw a substantial increase to $692,974 from $2,723 year-over-year, an increase of over 25,000%.
• The primary driver of revenue growth was RNK Health's non-clinical administrative services, contributing $441,227 in Q3 2025 and $634,177 for the nine months ended September 30, 2025.
• Subscription services (Gaxos Labs SaaS) generated $57,042 in Q3 2025 and $57,648 for the nine months, up from $0 in the prior year periods.
• Net loss for Q3 2025 increased to $(1,140,873) from $(864,410) in Q3 2024, a 32.0% increase.
• Net loss for the nine months ended September 30, 2025, grew to $(3,197,507) from $(2,585,793) in the prior year, a 23.7% increase.
• Operating expenses for Q3 2025 rose by 99.5% to $1,813,026, primarily due to a 638.9% increase in advertising and marketing for RNK Health services.
• Cash balance as of September 30, 2025, was $914,183, a significant decrease from $14,398,099 at December 31, 2024.
• Short-term investments increased to $12,058,377 from $2,167,419 over the same period.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(3,120,632), an increase from $(2,512,166) in the prior year.
• The company acquired software and related technologies for $500,000 cash and 200,000 common shares (valued at $248,000) on February 24, 2025.

Sentiment

Score: 4

Explanation: The company achieved substantial revenue growth, primarily from new AI-powered health and subscription services, indicating successful product diversification. However, this growth came at a high cost, with significantly increased operating expenses, widening net losses, and a substantial reduction in cash reserves. The explicit need for future capital raises and continued operating losses temper the positive revenue developments, suggesting a challenging path to profitability and potential dilution for shareholders.

Positives

• Significant revenue growth in Q3 2025 to $498,271 from $2,704 in Q3 2024, primarily driven by RNK Health and Gaxos Labs subscriptions.
• RNK Health's non-clinical administrative services generated $441,227 in Q3 2025 and $634,177 for the nine months ended September 30, 2025, establishing a new and substantial revenue stream.
• Gaxos Labs' SaaS subscriptions contributed $57,042 in Q3 2025, indicating initial traction for its generative AI service for game developers.
• Improved basic and diluted net loss per common share for the nine months ended September 30, 2025, at $(0.42) compared to $(1.95) in the prior year, despite higher net loss, due to a significantly increased share count.
• Increased short-term investments to $12,058,377 as of September 30, 2025, from $2,167,419 at December 31, 2024, indicating strategic asset allocation.
• Successful launch and development of new initiatives like Gaxos Health and Gaxos Gaming Labs, expanding the company's AI-powered product portfolio.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $(1,140,873) from $(864,410) in the prior year, a 32.0% increase.
• Net loss for the nine months ended September 30, 2025, increased to $(3,197,507) from $(2,585,793) in the prior year, a 23.7% increase.
• Operating expenses for Q3 2025 increased by 99.5% to $1,813,026, largely due to a 638.9% increase in advertising and marketing expenses for RNK Health services, indicating a high burn rate.
• Cash balance significantly decreased to $914,183 as of September 30, 2025, from $14,398,099 at December 31, 2024, representing a substantial reduction in liquidity.
• Net cash used in operating activities for the nine months ended September 30, 2025, increased to $(3,120,632) from $(2,512,166) in the prior year, indicating higher operational cash burn.
• No cash flows from financing activities for the nine months ended September 30, 2025, compared to $5,872,746 provided in the prior year, highlighting reliance on existing capital and prior raises.
• The company expects to continue generating operating losses in the foreseeable future due to corporate overhead, research and development, and public company costs.

Risks

• Ability to obtain additional funds for operations.
• Financial performance, including revenues, cost of revenues, operating expenses, and ability to attain and sustain profitability.
• Ability to attract and retain users.
• Ability to attract and retain advertisers.
• Ability to compete effectively with existing competitors and new market entrants.
• Ability to successfully expand in existing markets and penetrate new markets.
• Ability to effectively manage growth and future expenses.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to comply with modified or new laws and regulations applying to the business, competitors, and industry.
• Ability to attract and retain qualified key management and technical personnel.
• Medical Partners' telehealth business could be adversely affected by ongoing legal challenges to their business model or by new state actions restricting their ability to provide the full range of services in certain states.
• Dependence on states' treatment of medicine under laws, rules, and policies governing physician-supervised services, which are subject to changing political, regulatory, and other influences.
• Evolving government regulations and enforcement activities may require increased costs or adversely affect results of operations, potentially leading to business model modifications, fines, or termination of operations in certain jurisdictions.

Future Outlook

The company expects to continue generating operating losses in the foreseeable future due to corporate overhead, research and development, and costs associated with being a public company. It believes its existing working capital and cash on hand, including proceeds from December 2024 securities purchase agreements, will provide sufficient cash to meet operating needs and debt requirements for the next twelve months. However, significant capital will be required to sustain operations and execute its longer-term business plan, potentially necessitating additional debt or equity financing if business downturns or expense increases occur. Research and development expenses are expected to increase as Gaxos Health and RNK Health development accelerates.

Management Comments

• "We expect to continue to generate operating losses in the foreseeable future, mostly due to corporate overhead, research and development, and costs of being a public company."
• "We believe that our existing working capital and cash on hand will provide sufficient cash to enable the Company to meet its operating needs and debt requirements for the next twelve months from the issuance date of this report."
• "We will require significant amounts of capital to sustain operations, and we will need to make the investments we need to execute our longer-term business plan to support new technologies and help advance innovation."
• "Absent generation of sufficient revenue from the execution of our long-term business plan, we will need to obtain debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly-traded company or from operations."
• "We plan to pursue our plans with respect to the research and development of our products which will require resources beyond those that we currently have, ultimately requiring additional capital from third party sources."
• "We believe the net proceeds received from the December 2024 securities purchase agreements as discussed above will be sufficient to meet our financial obligations for at least the next 12 months."

Industry Context

Gaxos.AI is positioning itself at the intersection of two rapidly growing sectors: artificial intelligence and health/wellness, alongside its established gaming segment. The significant revenue growth from RNK Health and Gaxos Labs subscriptions indicates a successful pivot and expansion into AI-powered solutions for health and game development. This aligns with broader industry trends emphasizing personalized health solutions and the integration of generative AI in content creation. The company's focus on reducing creative asset development time in gaming and optimizing personal health through AI reflects a strategic move to capitalize on high-demand, innovative technologies. However, the substantial increase in advertising and marketing expenses for RNK Health suggests a competitive landscape requiring significant investment to gain market share.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceeding against the company that is believed could have a material adverse effect on business, operating results, cash flows, or financial condition.

Related Party Transactions

• On September 17, 2025, the company made a $10,000 investment into RPM Interactive, Inc., receiving a promissory note bearing 7.0% interest and maturing on September 17, 2026.
• On May 16, 2024, the company purchased 666,660 common shares of RPM Interactive, Inc. for $199,998, which are held as investment in equity securities at fair value.

Stakeholder Impact

• Shareholders face potential for dilution from future capital raises due to the company's stated need for additional financing. Increased losses and cash burn could negatively impact share value, but significant revenue growth from new segments offers long-term potential.
• Employees benefit from continued investment in R&D for new platforms (Gaxos Health, RNK Health) suggesting ongoing employment opportunities, and stock-based compensation plans are in place.
• Customers of Gaxos Labs, Gaxos Gaming, and Gaxos Health are offered new AI-powered solutions aimed at enhancing user experience and providing innovative tools. RNK Health provides access to medications, supplements, and wellness products/services.
• Creditors may view the company's liquidity position with caution, despite management's assurance of sufficient cash for the next 12 months, given the high cash burn and explicit need for future financing.
• Partners, such as Nekwellness and the Medical Partner for RNK Health, are integral to a key revenue stream, but regulatory risks in the telehealth sector could impact these relationships and associated revenues.

Next Steps

• Continue development of Gaxos Health and RNK Health platforms, expecting increased research and development expenses.
• Implement growth strategy to generate sufficient revenue to offset operating losses.
• Potentially seek additional debt or equity financing to sustain operations and execute the long-term business plan.
• Offer new features and charge fees for Gaxos Gaming once a critical mass of users is achieved.
• Comply with new accounting guidance ASU 2024-03, effective for fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

While Gaxos.AI demonstrates impressive revenue growth driven by its strategic expansion into AI-powered health and subscription services, the substantial increase in net losses and cash burn raises concerns about its path to profitability and financial sustainability. The company explicitly acknowledges the need for significant future capital, which could lead to further shareholder dilution. The improved EPS is primarily due to a higher share count rather than improved operational profitability. Given the high growth potential in its new segments balanced against significant operational losses and the need for additional financing, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to convert revenue growth into sustainable profits and secure future funding without excessive dilution.

Keywords

AI, Artificial Intelligence, Health Tech, Gaming, Telehealth, Generative AI, SaaS, RNK Health, Gaxos Labs, Gaxos Gaming, Gaxos Health, SEC Filing, 10-Q, Financial Report, Technology